MAM
Purplle announces #PurplleWaliDiwali with Sara Ali Khan
Mumbai: Beauty e-commerce platform Purplle has launched its festive campaign called ‘Purplle Wali Diwali’ with Bollywood star Sara Ali Khan. As a part of this sale, consumers will get a chance to choose their free gift on every order, said the brand. The Purplle Diwali sale will go live from 20-26 October.
The campaign film showcases Khan grooving to “Yeh Diwali Purplle Wali” giving the original song a twist, voiced by singer Anushka Manchanda.
“We wanted to make this Diwali even more special for our consumers during our biggest sale of the season,” said Purplle chief business officer Nippun Aneja. “This year everyone will have the freedom to choose their very own free Diwali gift every time they shop with us, on every order they place. We want this to truly be a Purplle Wali Diwali, celebrated with Sara Ali Khan, and the best of beauty for all.”
Rolled out across television, print, digital, and social media channels, the 360-degree campaign will also witness over 3,000 influencers grooving to the song and choosing their beauty best this Diwali, said the brand in a statement.
A host of beauty products, including, hair straighteners, eye-shadow palettes, primers, highlighters, mascaras, and a lot more will be up for grabs and consumers stand a chance to win the coveted ‘Papa Don’t Preach Lehenga’ worn by Khan in the campaign film, it added.
“We created a fun, quirky, celebration, in the Purplle world, leveraging the brand ethos. With sharp lyrics, we ensured our core communication stands out on a unique, trendy canvas,” stated Spring Marketing Capital founder and creative partner Arun Iyer, on the execution of the campaign.
“Purplle stands for inclusive and accessible beauty for all, and this Diwali they have empowered consumers to choose a free gift of their choice and claim some of the coolest beauty products,” said Khan. “Bringing alive the essence of the campaign through a catchy tune, a quirky hook step, and recreating Bollywood’s most iconic song has been exciting.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
